|
|
|
|
Pfizer Q4 profit, FY10 outlook fall short of estimates
2/3/2010 9:33 AM ET RELATED NEWS Trade PFE now with TOP MARKET NEWS (RTTNews) - Pharmaceutical giant Pfizer Inc.(PFE: News ) on Wednesday reported a profit for the fourth quarter that almost tripled from last year, when results were negatively impacted by a...
|
|
|
Pfizer Q4 Profit, FY10 Outlook Falls Short Of Estimates - Update
(RTTNews) - Pharmaceutical giant Pfizer Inc.(PFE) on Wednesday reported a profit for the third quarter that almost tripled from last year, when results were negatively impacted by a hefty charge. Revenues for the quarter surged 34% from last year.
|
|
|
CNS Therapeutics - A World Market Review
NEW YORK, Jan.29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: While the available CNS therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes...
|
|
|
CNS Therapeutics - A World Market Review
NEW YORK, Jan.29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: While the available CNS therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes...
|
|
|
CNS Therapeutics - A World Market Review
NEW YORK, Jan.29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: While the available CNS therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes...
|
|
|
CNS Therapeutics - A World Market Review
NEW YORK, Jan.29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: While the available CNS therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes...
|
|
|
CNS Therapeutics - A World Market Review
NEW YORK, Jan.29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: While the available CNS therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes...
|
|
|
CNS Therapeutics - A World Market Review
NEW YORK, Jan.29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: While the available CNS therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes...
|
|
|
CNS Therapeutics - A World Market Review
NEW YORK, Jan.29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: While the available CNS therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes...
|
|
|
CNS Therapeutics - A World Market Review
NEW YORK, Jan.29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: While the available CNS therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes...
|
|
|
CNS Therapeutics - A World Market Review
NEW YORK, Jan.29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: While the available CNS therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes...
|
|
|
CNS Therapeutics - A World Market Review
NEW YORK, Jan.29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: http://www.reportlinker.com/p0164268/CNS-Therapeutics---A-World-Market-Review.html While the available CNS therapies can slow down...
|
|
|
CNS Therapeutics - A World Market Review
NEW YORK, Jan.29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: While the available CNS therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes...
|
|
|
CNS Therapeutics - A World Market Review
PR Newswire /PRNewswire/ -- Reportlinker.com announces that a new is available in its catalogue: http://www.reportlinker.com/p0164268/CNS-Therapeutics---A-World-Market-Review.html While the available CNS therapies can slow down deteriorating condition of...
|
|
|
CNS Therapeutics - A World Market Review
NEW YORK, Jan.29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: While the available CNS therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes...
|
|
|
CNS Therapeutics - A World Market Review
NEW YORK, Jan.29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: While the available CNS therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes...
|
|
|
CNS Therapeutics - A World Market Review
NEW YORK, Jan.29 NEW YORK While the available CNS therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes with potential to stop or reverse the disease's progression. Continuing switch over of patients...
|
|
|
CNS Therapeutics - A World Market Review
NEW YORK, Jan.29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: While the available CNS therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes...
|
|
|
CNS Therapeutics - A World Market Review
NEW YORK, Jan.29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: While the available CNS therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes...
|
|
|
CNS Therapeutics - A World Market Review
GA_googleFillSlot("Press336"); GA_googleFillSlot("Press160"); NEW YORK, Jan.29 /PRNewswire/ -- Reportlinker.com announces that a new is available in its catalogue: http://www.reportlinker.com/p0164268/CNS-Therapeutics---A-World-Market-Review.html While the...
|
|
|
CNS Therapeutics - A World Market Review
NEW YORK, Jan.29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: While the available CNS therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes...
|
|
|
CNS Therapeutics A World Market Review
NEW YORK, Jan.29 /PRNewswire/ Reportlinker.com announces that a new market research report is available in its catalogue: http://www.reportlinker.com/p0164268/CNS-TherapeuticsA-World-Market-Review.html While the available CNS therapies can slow down...
|
|
|
Why the Bribery Bill may turn out to be a bitter pill for the industry to swallow
The Bribery Bill has imposed a new layer of regulation on the UK pharmaceutical sector, says John Benstead On 1 December 2009 Robert Dougall, a former vice-president at DePuy International Ltd, was ordered to stand trial for conspiracy to corrupt.The Serious...
|
|
|
FDA actions in brief, January 2010 (Cymbalta, Zyprexa, Zyprexa Relprevv, Intelence, Kalbitor, Istodax, Geodon,
Drugs and indications recently approved by the FDA Formulary Duloxetine HCl (Cymbalta, Eli Lilly) was approved for the maintenance treatment of generalized anxiety disorder in adults.Olanzapine (Zyprexa, Eli Lilly) was approved as treatment for schizophrenia...
|
|
|
FDA actions in brief, January 2010 (Cymbalta, Zyprexa, Zyprexa Relprevv, Intelence, Kalbitor, Istodax, Geodon, Vagifem, Seroquel XR, Clonidine ER Suspension, Clonidine ER Tablets, Wilate)
Duloxetine HCl (Cymbalta, Eli Lilly) was approved for the maintenance treatment of generalized anxiety disorder in adults.Olanzapine (Zyprexa, Eli Lilly) was approved as treatment for schizophrenia and bipolar disorder in teenagers. Olanzapine extended...
|
